Sign In
Buy UTMD
$70.52
+0.95 (+1.37%)
At Close: Jul 31, 2026
Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend
10:00am, Tuesday, 04'th Nov 2025
SALT LAKE CITY, UT / ACCESS Newswire / November 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Kevin C. Timken, Esq to its Board of Directors.
UTMD's Q3 Earnings Dip Y/Y on Trade Disruptions, Margins Squeeze
02:31pm, Wednesday, 29'th Oct 2025
Utah Medical's Q3 earnings fell 20% year over year as order cancellations and tariffs pressured margins. Growth in U.S. Filshie devices and direct sales helped partially offset declines.
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2025
09:00am, Thursday, 23'rd Oct 2025
SALT LAKE CITY, UT / ACCESS Newswire / October 23, 2025 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2025 financial results that w
UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%
02:01pm, Wednesday, 30'th Jul 2025
Utah Medical's Q2 earnings decrease year over year on lower OEM sales and weak international demand, though cost controls helped cushion margins.
Utah Medical Products, Inc. Announces Quarterly Dividend
10:00am, Tuesday, 29'th Jul 2025
SALT LAKE CITY, UT / ACCESS Newswire / July 29, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty and one-half cents (
Utah Medical Products Reports Q2 Decline
03:54am, Friday, 25'th Jul 2025
Utah Medical Products Reports Q2 Decline
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2025
09:00am, Thursday, 24'th Jul 2025
SALT LAKE CITY, UT / ACCESS Newswire / July 24, 2025 / Utah Medical Products, Inc. [Nasdaq:UTMD] reports second calendar quarter (2Q) and first half (1H) 2025 financial results which are consistent wi
Utah Medical Products: Deep Discount Is Drawing One Legendary Investor's Interest
07:09am, Thursday, 03'rd Jul 2025
I reiterate my strong buy on UTMD, citing its robust balance sheet, disciplined capital allocation, and 43% upside to my $82.22 price target. Revenue headwinds appear to be stabilizing, with legendary
Utah Medical Products, Inc. Announces Quarterly Dividend
10:00am, Tuesday, 06'th May 2025
SALT LAKE CITY, UT / ACCESS Newswire / May 6, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty and one-half cents ($.
Stock Picks From Seeking Alpha's April 2025 New Analysts
08:00am, Tuesday, 06'th May 2025
In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasi
Utah Medical Q1 Earnings Drop 16% on Sales Slump, Stock Up 1%
02:35pm, Monday, 05'th May 2025
UTMD's Q1 2025 earnings fall 16% amid weak OEM sales, FX pressures and higher taxes, despite lower litigation costs and a strong cash position.
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2025
09:00am, Tuesday, 29'th Apr 2025
SALT LAKE CITY, UT / ACCESS Newswire / April 29, 2025 / In the first calendar quarter (1Q) of 2025, Utah Medical Products, Inc. (Nasdaq:UTMD) attained financial results consistent with its previously
Utah Medical Products: Quietly Profitable--A Deep Value Gem Hiding In The Open
10:58am, Wednesday, 16'th Apr 2025
Utah Medical Products develops and manufactures medical devices focused on women's health, obstetrics, gynecology, and blood pressure monitoring. The company's stock price has declined due to a drop i
Utah Medical Products, Inc. Announces Quarterly Dividend
10:00am, Tuesday, 04'th Feb 2025
SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.305) per
Utah Medical's EPS Declines 27% Y/Y in Q4, Stock Drops 5%
12:51pm, Friday, 31'st Jan 2025
UTMD's Q4 EPS drops 27.4% year over year, and revenues fall 25.8% on weak PendoTECH sales. Revenues are expected to decline further in 2025.
